Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05727163
What this trial is testing

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Who this might be right for
Colorectal Cancer Metastatic
Sun Yat-sen University 194
Early research (Phase 1)Looking for participantsNCT03454035
What this trial is testing

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Who this might be right for
Tumor, SolidPancreatic CancerMelanoma
UNC Lineberger Comprehensive Cancer Center 45
Testing effectiveness (Phase 2)Looking for participantsNCT06218810
What this trial is testing

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal CancerMicrosatellite Stable Colorectal CarcinomaRAS Mutation+1 more
Fudan University 53
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)Ended earlyNCT02175654
What this trial is testing

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

Who this might be right for
Colorectal NeoplasmsMetastatic Disease
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 15
Testing effectiveness (Phase 2)Study completedNCT05340621
What this trial is testing

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Who this might be right for
RAS MutationNRAS Gene MutationMelanoma
OnKure, Inc. 36
Large-scale testing (Phase 3)Looking for participantsNCT06881784
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more
Revolution Medicines, Inc. 590
Testing effectiveness (Phase 2)Looking for participantsNCT05379985
What this trial is testing

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Revolution Medicines, Inc. 754
Testing effectiveness (Phase 2)Study completedNCT02448290
What this trial is testing

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

Who this might be right for
Gastric Adenocarcinoma
Samsung Medical Center 25
Testing effectiveness (Phase 2)Ended earlyNCT03745326
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Gastrointestinal CancerPancreatic CancerGastric Cancer+2 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Study completedNCT01450319
What this trial is testing

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

Who this might be right for
Colorectal Neoplasms
Merck KGaA, Darmstadt, Germany 73
Early research (Phase 1)Study completedNCT01337765
What this trial is testing

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Who this might be right for
Unspecified Adult Solid Tumor, Protocol SpecificSolid Tumor
Pfizer 29
Large-scale testing (Phase 3)Active Not RecruitingNCT05171660
What this trial is testing

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IV
Second Affiliated Hospital, Zhejiang University, School of Medicine 446
Testing effectiveness (Phase 2)Study completedNCT02414009
What this trial is testing

Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients

Who this might be right for
Metastatic Colorectal Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 82
Testing effectiveness (Phase 2)Study completedNCT01298570
What this trial is testing

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
UNC Lineberger Comprehensive Cancer Center 181
Testing effectiveness (Phase 2)Looking for participantsNCT05735717
What this trial is testing

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Who this might be right for
Hematologic MalignancyAcute LeukemiaRemission+21 more
Masonic Cancer Center, University of Minnesota 70
Testing effectiveness (Phase 2)Ended earlyNCT02418000
What this trial is testing

E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Who this might be right for
AMLMDSCMML
Spirita Oncology, LLC 27
Testing effectiveness (Phase 2)Study completedNCT05593328
What this trial is testing

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Who this might be right for
Colorectal CancerMetastatic Colorectal Cancer
Cardiff Oncology 23
Testing effectiveness (Phase 2)Study completedNCT01693068
What this trial is testing

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Who this might be right for
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
EMD Serono 194
Testing effectiveness (Phase 2)Looking for participantsNCT07213570
What this trial is testing

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
National Cancer Institute, Naples 60
Next Page